Adverse reactions to the Johnson & Johnson vaccine cause some states to pause distribution; the Biden administration proposes creation of a $6.5 billion medical research agency aiming to cure cancer and other diseases; Pfizer/BioNTech seeks expansion of its COVID-19 vaccine emergency use authorization in adolescents.
As reported by CBS News, Georgia has become the third state to temporarily shut down a vaccine site distributing the Johnson & Johnson (J&J) COVID-19 vaccine after 8 people experienced adverse reactions to the shot. Moreover, J&J has announced a major distribution setback as this week’s shipment to states will be reduced by 86%. Adverse reactions were also reported earlier last week in North Carolina, in 18 people, and Colorado, in 11 people, with symptoms including dizziness, nausea, and fainting. For all 3 of the US approved COVID-19 vaccines—Pfizer, Moderna, and J&J—one-tenth of all recipients have experienced adverse effects.
Last Friday, the Biden administration proposed the creation of a $6.5 billion medical research agency with the goal of quickly developing cures for diseases, including cancer, Alzheimer disease, and diabetes. STAT reports that the new agency would be housed within the National Institutes of Health (NIH), with the $6.5 billion sum amounting to more than the current budget for the largest agency within the NIH, the National Cancer Institute. If established, the agency would mark a significant shift from basic science projects to higher-risk ones that more directly target medical breakthroughs in each disease.
According to The New York Times, Pfizer and BioNTech requested that the FDA expand its emergency use authorization for their COVID-19 vaccine to adolescents aged 12 to 15 years following positive trial results in these populations. In an announcement by both companies this past Friday, Pfizer/BioNTech are planning to request similar authorizations from health agencies worldwide. If granted expanded authorization, adolescents of this age group could start getting vaccinated before the start of school in the fall. Moderna is also testing its vaccine in a study of 12- to 17-year-olds, with Pfizer and Moderna currently conducting studies among children under the age of 12.
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
AHN’s Center for Inclusion Health Personalizing Equitable Care Delivery for Marginalized Communities
February 28th 2023On this episode of Managed Care Cast, we speak with Elizabeth Cuevas, MD, division chief of Allegheny Health Network’s (AHN) Center for Inclusion Health, on prevalent health inequities facing marginalized communities and strategies to identify and address these issues.
Listen
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More